Conclusions: Alterations of PSMA-radioligand uptake are seen in bone and pulmonary metastases but not in lymph node metastases after initiation of systemic treatment in patients with mRCC. Here, FOLH1 is linked to metastatic malignant neoplasm in the lymph nodes.